Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma

Seminars in Diagnostic Pathology

Volumn 32, Issue 5, 2015, Pages 352-361

  Shia, Jinru ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CMMR D; Lynch syndrome; Lynch like syndrome; Microsatellite instability; MMR IHC; Sporadic MSI cancer

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN; PROTEIN MLH1; PROTEIN MSH2; TUMOR MARKER;

ARTICLE; BRAF GENE; COLORECTAL CARCINOMA; DNA DETERMINATION; EPCAM GENE; GENE; GENE DELETION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MEDICOLEGAL ASPECT; METHYLATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MLH1 GENE; MOLECULAR DYNAMICS; MSH2 GENE; PRIORITY JOURNAL; SCREENING TEST; SOMATIC MUTATION; ALGORITHM; CHEMISTRY; CLINICAL PATHWAY; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE;

ALGORITHMS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CRITICAL PATHWAYS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS;

EID: 84940446904     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2015.02.018     Document Type: Article

References (65)

1. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010, 138(6):2073-2087. (e2073).
2. Shia J., Holck S., Depetris G., Greenson J.K., Klimstra D.S. Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer 2013, 12(2):241-260.
3. Lynch H.T., Drescher K., Knezetic J., Lanspa S. Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review. Curr Treat Options Oncol 2014.
4. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349(3):247-257.
5. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010, 28(20):3219-3226.
6. Konstantinopoulos P.A., Matulonis U.A. POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing. Cancer 2014.
7. Burn J., Gerdes A.M., Macrae F., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378(9809):2081-2087.
8. Vasen H.F., Mecklin J.P., Khan P.M., Lynch H.T. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34(5):424-425.
9. Vasen H.F., Watson P., Mecklin J.P., Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116(6):1453-1456.
10. EGAPP Working Group Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009, 11(1):35-41.
11. Peltomaki P., Offerhaus G.J.A., Vasen H.F.A. Lynch syndrome. WHO Classification of Tumours of the Digestive System 2010, 152-155. IARC Press, Lyon, France. F.T.C.F. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
12. De Jong A.E., Morreau H., Van Puijenbroek M., et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology 2004, 126(1):42-48.
13. Sehgal R., Sheahan K., O'Connell P.R., Hanly A.M., Martin S.T., Winter D.C. Lynch syndrome: an updated review. Genes 2014, 5(3):497-507.
14. Giardiello F.M., Allen J.I., Axilbund J.E., et al. Guidelines on genetic evaluation and management of lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum 2014, 57(8):1025-1048.
15. Vasen H.F., Moslein G., Alonso A., et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007, 44(6):353-362.
16. Rodriguez-Soler M., Perez-Carbonell L., Guarinos C., et al. Risk of cancer in cases of suspected Lynch syndrome without germline mutation. Gastroenterology 2013, 144(5):926-932. [e921; quiz e913-e924].
17. Boland C.R. The mystery of mismatch repair deficiency: Lynch or Lynch-like?. Gastroenterology 2013, 144(5):868-870.
18. Tutlewska K., Lubinski J., Kurzawski G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome-literature review. Hered Cancer Clin Pract 2013, 11(1):9.
19. Niessen R.C., Hofstra R.M., Westers H., et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009, 48(8):737-744.
20. Hitchins M.P., Lynch H.T. Dawning of the epigenetic era in hereditary cancer. Clin Genet 2014, 85(5):413-416.
21. Rhees J., Arnold M., Boland C.R. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer 2014, 13(2):219-225.
22. Mensenkamp A.R., Vogelaar I.P., van Zelst-Stams W.A., et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014, 146(3):643-646. [e648].
23. Morak M., Heidenreich B., Keller G., et al. Biallelic MUTYH mutations can mimic Lynch syndrome. Eur J Hum Genet 2014.
24. Castillejo A., Vargas G., Castillejo M.I., et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J Cancer 2014.
25. Sourrouille I., Coulet F., Lefevre J.H., et al. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. Fam Cancer 2013, 12(1):27-33.
26. Haraldsdottir S., Hampel H., Tomsic J., et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014.
27. Geurts-Giele W.R., Leenen C.H., Dubbink H.J., et al. Somatic aberrations of mismatch repair genes as a cause of microsatellite-instable cancers. J Pathol 2014.
28. Wimmer K., Kratz C.P., Vasen H.F., et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'Care for CMMRD' (C4CMMRD). J Med Genet 2014, 51(6):355-365.
29. Li F., Mao G., Tong D., et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 2013, 153(3):590-600.
30. Diouf B., Cheng Q., Krynetskaia N.F., et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 2011, 17(10):1298-1303.
31. Lindor N.M. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. Surg Oncol Clin N Am 2009, 18(4):637-645.
32. Shiovitz S., Copeland W.K., Passarelli M.N., et al. Characterisation of Familial Colorectal Cancer Type X, Lynch syndrome, and non-familial colorectal cancer. Br J Cancer 2014.
33. Peterlongo P., Mitra N., Sanchez de Abajo A., et al. Increased frequency of disease-causing MYH mutations in colon cancer families. Carcinogenesis 2006, 27(11):2243-2249.
34. Nieminen T.T., Abdel-Rahman W.M., Ristimaki A., et al. BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 2011, 141(1):e23-e26.
35. Morak M., Massdorf T., Sykora H., Kerscher M., Holinski-Feder E. First evidence for digenic inheritance in hereditary colorectal cancer by mutations in the base excision repair genes. Eur J Cancer 2011, 47(7):1046-1055.
36. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96(4):261-268.
37. Kastrinos F., Steyerberg E.W., Mercado R., et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011, 140(1):73-81.
38. Chen S., Wang W., Lee S., et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. J Am Med Assoc 2006, 296(12):1479-1487.
39. Shia J., Ellis N.A., Paty P.B., et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003, 27(11):1407-1417.
40. Alexander J., Watanabe T., Wu T.T., Rashid A., Li S., Hamilton S.R. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001, 158(2):527-535.
41. Shia J., Klimstra D.S., Nafa K., et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005, 29(1):96-104.
42. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008, 10(4):293-300.
43. Martin-Lopez J.V., Barrios Y., Medina-Arana V., et al. The hMSH2(M688R) Lynch syndrome mutation may function as a dominant negative. Carcinogenesis 2012, 33(9):1647-1654.
44. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58(22):5248-5257.
45. Niu B., Ye K., Zhang Q., et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 2013.
46. Salipante S.J., Scroggins S.M., Hampel H.L., Turner E.H., Pritchard C.C. Microsatellite instability detection by next generation sequencing. Clin Chem 2014, 60(9):1192-1199.
47. Parsons M.T., Buchanan D.D., Thompson B., Young J.P., Spurdle A.B. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012, 49(3):151-157.
48. Kawaguchi M., Yanokura M., Banno K., et al. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int J Oncol 2009, 34(6):1541-1547.
49. Hampel H., Frankel W.L., Martin E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008, 26(35):5783-5788.
50. Ladabaum U., Wang G., Terdiman J., et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011, 155(2):69-79.
51. Boland C.R., Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 2010, 138(7):2197.e1-2197.e7.
52. Hampel H. NCCN increases the emphasis on genetic/familial high-risk assessment in colorectal cancer. J Natl Compr Canc Netw 2014, 12(Suppl 5):829-831.
53. Kidambi T.D., Blanco A., Myers M., Conrad P., Loranger K., Terdiman J.P. Selective versus universal screening for Lynch syndrome: a six-year clinical experience. Dig Dis Sci 2014.
54. Beamer L.C., Grant M.L., Espenschied C.R., et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 2012, 30(10):1058-1063.
55. Hamilton S.R., Bosman F.T., Boffetta P., et al. Carcinoma of the colon and rectum. WHO Classification of Tumours of the Digestive System 2010, 134-146. IARC Press, Lyon, France. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
56. Kakar S., Smyrk T.C. Signet ring cell carcinoma of the colorectum: correlations between microsatellite instability, clinicopathologic features and survival. Mod Pathol 2005, 18(2):244-249.
57. Hartman D.J., Nikiforova M.N., Chang D.T., et al. Signet ring cell colorectal carcinoma: a distinct subset of mucin-poor microsatellite-stable signet ring cell carcinoma associated with dismal prognosis. Am J Surg Pathol 2013, 37(7):969-977.
58. Xiao H., Yoon Y.S., Hong S.M., et al. Poorly differentiated colorectal cancers: correlation of microsatellite instability with clinicopathologic features and survival. Am J Clin Pathol 2013, 140(3):341-347.
59. Sinicrope F.A., Foster N.R., Thibodeau S.N., et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011, 103(11):863-875.
60. Karamurzin Y., Zeng Z., Stadler Z.K., et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol 2012, 43(10):1677-1687.
61. Medina-Arana V., Delgado L., Gonzalez L., et al. Adrenocortical carcinoma, an unusual extracolonic tumor associated with Lynch II syndrome. Fam Cancer 2011, 10(2):265-271.
62. Blake C., Tsao J.L., Wu A., et al. Stepwise deletions of polyA sequences in mismatch repair-deficient colorectal cancers. Am J Pathol 2001, 158(5):1867-1870.
63. Pritchard C.C., Smith C., Salipante S.J., et al. ColoSeq provides comprehensive Lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14(4):357-366.
64. Gould-Suarez M., El-Serag H.B., Musher B., Franco L.M., Chen G.J. Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome. Dig Dis Sci 2014.
65. De Lellis L., Aceto G.M., Curia M.C., et al. Integrative analysis of hereditary nonpolyposis colorectal cancer: the contribution of allele-specific expression and other assays to diagnostic algorithms. PLoS One 2013, 8(11):e81194.